<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kiora Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc</link>
<description>Latest news and press releases for Kiora Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kiora-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358eaf78dffbe2df10151a.webp</url>
<title>Kiora Pharmaceuticals Inc</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc</link>
</image>
<item>
<title>Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kioras-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kioras-phase-1-abacus-study-of-kio-301-in-retinitis-pigmentosa-published-in-nature-medicine-phase-2-trial-underway</guid>
<pubDate>Tue, 14 Apr 2026 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program aimed at restoring light responsiveness with a small molecule "photoswitch" in patients with the advanced inherited retinal disease, retinitis pigmentosa. The publication may be accessed at the following link...</description>
</item>
<item>
<title>Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/plus-therapeutics-appoints-eric-j-daniels-md-mba-as-chief-development-officer-to-advance-clinical-pipeline-1</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/plus-therapeutics-appoints-eric-j-daniels-md-mba-as-chief-development-officer-to-advance-clinical-pipeline-1</guid>
<pubDate>Thu, 09 Apr 2026 11:30:00 GMT</pubDate>
<description>Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-focused pipelineHOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of E</description>
</item>
<item>
<title>Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-announces-private-placement-for-up-to-dollar24-million-led-by-perceptive-advisors</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-announces-private-placement-for-up-to-dollar24-million-led-by-perceptive-advisors</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Sole investors are Perceptive Advisors (new) and ADAR1 Capital Management Encinitas, California--(Newsfile Corp. - April 7, 2026) - Kiora Pharmaceuticals,</description>
</item>
<item>
<title>Kiora Pharmaceuticals Announces Management Team Changes</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-announces-management-team-changes</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-announces-management-team-changes</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that Eric J.</description>
</item>
<item>
<title>Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-company-advances-retinal-disease-pipeline-with-two-active-phase-2-clinical-trials</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-company-advances-retinal-disease-pipeline-with-two-active-phase-2-clinical-trials</guid>
<pubDate>Wed, 25 Mar 2026 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases.Key fourth-quarter, full-year 2025, and recent corporate highlights include:Advanced KIO-301 from regulatory clearance to patient dosing in ABACUS-2, a Phase 2...</description>
</item>
<item>
<title>Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-to-present-at-oppenheimers-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-to-present-at-oppenheimers-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET.A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section. A replay of the webcast will be available for approximately 90 days.About Kiora...</description>
</item>
<item>
<title>Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/retinal-disease-expert-dr-taiji-120000830</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/retinal-disease-expert-dr-taiji-120000830</guid>
<pubDate>Tue, 27 Jan 2026 12:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to its Scientific Advisory Board. As an advisor, Dr. Sakamoto, currently the Chair of Ophthalmology at Kagoshima University, will contribute clinical and scientific insights to Kiora as it develops new therapeutics to address retinal diseases with high unmet needs. "As we deepen our...</description>
</item>
<item>
<title>Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-granted-u-patent-114500635</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-granted-u-patent-114500635</guid>
<pubDate>Mon, 01 Dec 2025 11:45:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on additional and novel formulations of the KIO-100 family of compounds, This patent allows for additional delivery options, expanding the potential therapeutic utility of the active pharmaceutical ingredient (API) in KIO-104. This newly issued patent specifically covers a novel formulation of the API</description>
</item>
<item>
<title>Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-third-quarter-110000229</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-third-quarter-110000229</guid>
<pubDate>Fri, 07 Nov 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided an update on its pipeline of small molecules for the treatment of retinal diseases. Key third quarter and 2025 year-to-date corporate highlights include:Continued recruitment and patient dosing in KLARITY, an open-label Phase 2 clinical trial evaluating KIO-104 for the treatment of patients with...</description>
</item>
<item>
<title>Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-joins-rare-x-130000112</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-joins-rare-x-130000112</guid>
<pubDate>Thu, 30 Oct 2025 13:00:00 GMT</pubDate>
<description>Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate collaboration among advocacy, research, and industry stakeholders to advance research leading to vision-improving therapies. The Vision Consortium aims to transform the lives of people affected by rare ocular disorders by identifying clinical trial ready populations, ensuring meaningful</description>
</item>
<item>
<title>Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-participate-2025-maxim-110000436</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-participate-2025-maxim-110000436</guid>
<pubDate>Wed, 15 Oct 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth Summit in New York and give an overview of its development pipeline at Eyecelerator @ AAO 2025 in Orlando. Maxim Growth Summit Ophthalmology Panel DetailsTitle: A vision of innovation; Advances in biotechnology have spurred innovation in the management of diseases affecting our most used...</description>
</item>
<item>
<title>Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-webcast-demand-presentation-110000711</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-webcast-demand-presentation-110000711</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 27th Annual Global Investment Conference.Presentation DetailsDate:Friday, September 5th, 2025Time:7:00 am Eastern Daylight TimeLink:https://ir.kiorapharma.com/news-events/events The replay will be..</description>
</item>
<item>
<title>Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-second-quarter-110000156</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-second-quarter-110000156</guid>
<pubDate>Fri, 08 Aug 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key second quarter and 2025 year-to-date corporate highlights include:KIO-104Initiated KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of patients with retinal inflammation.Strengthened and extended m</description>
</item>
<item>
<title>Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-showcase-retinal-disease-110000349</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-showcase-retinal-disease-110000349</guid>
<pubDate>Thu, 07 Aug 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - August 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its President and CEO, Brian M. Strem, Ph.D., will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Presentation DetailsDate:Wednesday, August 13, 2025 Time:7:00 am Eastern Daylight Time Link:https://ir.kiorapharma.com/news-events/events The replay will be av</description>
</item>
<item>
<title>Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-granted-u-patent-125500615</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-granted-u-patent-125500615</guid>
<pubDate>Tue, 22 Jul 2025 12:55:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment of a wide range of ocular diseases. This includes, but is not limited to, the following conditions: ocular inflammation, uveitis, age-related macular degeneration, and complications from refractive surgery. Additionally, the patent covers varying dosing schedules, necessary excipients, among oth</description>
</item>
<item>
<title>Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-senju-pharmaceutical-partner-110000539</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-senju-pharmaceutical-partner-110000539</guid>
<pubDate>Tue, 03 Jun 2025 11:00:00 GMT</pubDate>
<description>Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single digit million up-front payment, development, regulatory, and commercial milestones, plus tiered royalties on sales Encinitas, California--(Newsfile Corp. - June 3, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has granted Senju Pharmaceutical Co., Ltd. (Se</description>
</item>
<item>
<title>Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-first-quarter-110000969</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-first-quarter-110000969</guid>
<pubDate>Fri, 09 May 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key first quarter and 2025 year-to-date corporate highlights include:Received approval to initiate KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of retinal inflammation.Reported preclinical data on KIO-</description>
</item>
<item>
<title>Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-presents-vivo-preclinical-110000616</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-presents-vivo-preclinical-110000616</guid>
<pubDate>Mon, 05 May 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - May 5, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The findings further support KIO-104 as a promising therapeutic candidate for inflammatory and proliferative diseases of the retina that lead to vision threatening scarring. The presentat</description>
</item>
<item>
<title>Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-present-24th-annual-110000954</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-present-24th-annual-110000954</guid>
<pubDate>Fri, 04 Apr 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M. Strem, Ph.D., will provide an update on the progress of the Company's pipeline and its planned Phase 2 clinical trials of KIO-104 for the treatment of retinal inflammation and of KIO-301 ...</description>
</item>
<item>
<title>Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027</title>
<link>https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-2024-results-110000740</link>
<guid isPermaLink="true">https://6ix.com/company/kiora-pharmaceuticals-inc/news/kiora-pharmaceuticals-reports-2024-results-110000740</guid>
<pubDate>Tue, 25 Mar 2025 11:00:00 GMT</pubDate>
<description>Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key fourth quarter and 2025 year-to-date corporate highlights include:Received approval to initiate KLARITY, a Phase 2 trial of KIO-104 for the treatment retinal inflammation.Received approval to initiate ABACUS-2, a Phase 2 study of</description>
</item>
</channel>
</rss>